Categorynews

NT-814 by Bayer: A Non-Hormonal, Orally Administered, Potent and Selective Small Molecule Dual Antagonist of Neurokinin-1 and 3 receptors – Global Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com

March 10, 2021 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “NT-814 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This report provides a detailed market assessment of NT-814 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

NT-814 is a non-hormonal, orally administered, potent and selective small molecule dual antagonist of both the neurokinin-1 and 3 receptors. NT-814 addresses vasomotor symptoms by modulating a group of oestrogen sensitive neurones in the hypothalamus in the brain (the KNDy neurones), that in menopausal women due to the absence of oestrogen, become hyperactive and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of hot flashes and night sweats. It is being developed by Bayer.

“NT-814 – Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Vasomotor symptoms in 7 Major Markets. A detailed picture of the NT-814 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

The report provides the clinical trials information of NT-814 covering trial interventions, trial conditions, trial status, start and completion dates.

Scope of the Report

A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
Elaborated details on regulatory milestones and other development activities have been provided in this report.
The report also highlights the drug research and development activity details across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around NT-814.
The report contains forecasted sales for NT-814 till 2030.
Comprehensive coverage of the late-stage emerging therapies (Phase III) for Vasomotor symptoms.
The report also features the SWOT analysis with analyst insights and key findings of NT-814.

Report Highlights

In the coming years, the market scenario for Vasomotor symptoms is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence NT-814 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Other emerging products for Vasomotor symptoms are giving market competition to NT-814 and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of NT-814.
This in-depth analysis of the forecasted sales data of NT-814 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NT-814.

Key Questions Answered

Which company is developing NT-814 along with the phase of the clinical study?
What is the technology utilized in the development of NT-814?
What is the product type, route of administration and mechanism of action of NT-814?
What is the clinical trial status of the study and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NT-814 development?
What are the key designations that have been granted to NT-814?
What is the forecasted market scenario of NT-814?
What is the history of NT-814 and what is its future?
What is the forecasted sales of NT-814 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how these are giving competition to NT-814?
Which are the late-stage emerging therapies under development for the treatment of the Vasomotor symptoms?